Litcius/Paper detail

Orally Administered Platinum Nanomarkers for Urinary Monitoring of Inflammatory Bowel Disease

Dongtao Zhou, Yi Yin, Zhenxing Zhu, Yanfeng Gao, Jingjing Yang, Yongchun Pan, Yujun Song

2022ACS Nano47 citationsDOI

Abstract

Inflammatory bowel disease (IBD) is a chronic relapsing autoimmune disease with rising incidence worldwide. There is an increasing desire for non-invasive diagnostic tools to enable simple and sensitive IBD monitoring. Here, we report an orally administered nanosensor which will dissociate into ultrasmall platinum nanoclusters (PtNCs) in IBD-related inflammatory microenvironments. By exploiting the enzyme-mimicking activity of PtNCs and the precise bandpass filterability of kidney, the released-PtNCs can be detected in a scalable urinary readout, such as fluorescence and volumetric bar-chart chip (V-Chip), for point-of-care (POC) analysis. Our results demonstrate that the nanosensors exhibit significant signal differences between IBD-model mice and healthy mice, which is more sensitive than clinical ELISA assay based on fecal calprotectin. Such a non-invasive diagnostic modality significantly assists in the personalized assessment of pharmacological and follow-up efficacy. We envision that this modular conception will promote the rapid diagnosis of diverse diseases by changing specific responsive components.

Topics & Concepts

Inflammatory bowel diseaseCalprotectinMedicineNanosensorUrinary systemUlcerative colitisGold standard (test)DiseaseInternal medicineImmunologyNanotechnologyMaterials sciencePregnancy and Medication ImpactNanocluster Synthesis and ApplicationsAdvanced Nanomaterials in Catalysis
Orally Administered Platinum Nanomarkers for Urinary Monitoring of Inflammatory Bowel Disease | Litcius